Fe + Mg: the seasonal formula to combat fatigue and lack of concentration

Editorial note: this article was previously published and has been updated according to scientific and informative criteria. The content is for informational purposes only and does not replace medical advice.

IN BRIEF

• Iron and magnesium have distinct biological roles but both can influence fatigue, attention, and mood.
• Evidence shows that targeted treatment of iron deficiency can reduce fatigue in some groups; the effects of magnesium on mood and cramps are promising but with heterogeneous results.
• Certain medications (e.g., some diuretics, proton pump inhibitors) and medical conditions can increase the risk of deficiency of these minerals.
• Diagnosis is based on appropriate laboratory tests; supplementation is indicated when proven deficiencies exist and should be evaluated with a healthcare professional.

MAIN SECTION — Abstract: what does science say?

Definition: iron and magnesium are essential micronutrients that participate in diverse but complementary processes. Iron is a central component of hemoglobin and participates in oxygen transport and metabolic processes related to energy and cognitive function. Magnesium is a cofactor for hundreds of enzymes, important for electrolyte balance, muscle function, and mood regulation.

What the evidence shows: randomized clinical trials indicate that, in individuals with iron deficiency (even when not always with overt anemia), correcting iron status can reduce fatigue symptoms and sometimes improve cognitive parameters; however, the quality of evidence is variable. For magnesium, trials and meta-analyses suggest possible benefits on mood and some muscle symptoms, but results are not uniform and depend on population, chemical form, and dose.

Critical dependencies: practical effects depend on the presence/absence of documented deficiency, the form and dose of supplementation, the duration of therapy, and the clinical context (age, comorbidities, concomitant therapies).

Interpretive limits: many studies are heterogeneous in terms of deficiency definitions, measured outcomes, and methodological quality; therefore, results should be interpreted in terms of association and potential effect, not as universal proof of preventive or therapeutic efficacy.

What it means in practice

For those experiencing persistent fatigue or decreased concentration, the first reasonable action is to evaluate the presence of identifiable medical factors. Reference tests for iron include ferritin and transferrin saturation; for magnesium, serum measurement should be considered, despite its limitations as an indicator of total body content. Supplementation may be useful when tests document a deficiency or when a professional determines that the potential benefit outweighs the risks. Generalized and untargeted use of supplements is not recommended: dosages, chemical form, timing, and monitoring must be agreed upon with a doctor. Furthermore, some medications can reduce the absorption or increase the loss of these minerals; therefore, it is important to evaluate pharmacological history and coexisting conditions before starting supplements.

Iron: biological role, clinical evidence, and limitations

Iron is essential for hemoglobin synthesis and for numerous enzymes involved in energy metabolism. In practical terms, a reduction in iron stores can manifest as fatigue, difficulty concentrating, and reduced physical performance. Randomized studies have tested the effect of correcting iron status on fatigue and quality of life: an RCT in premenopausal women with iron deficiency showed improvements in fatigue after intravenous iron administration (ferric carboxymaltose) compared to placebo [1]. However, systematic reviews and guidelines emphasize the heterogeneity of studies and the limited quality in many cases, recommending that invasive therapies (e.g., IV iron) be reserved for selected situations or when oral absorption is ineffective or poorly tolerated [2].

For cognitive function, a review highlighted that some studies show improvements in aspects of attention and memory after restoring iron stores, but the outcomes are variable and often depend on how much iron indicators normalize [3]. When deciding on intervention, it is crucial to distinguish between documented deficiency and empirical intake: efficacy is primarily observed when the deficiency is actually present.

Which tests to consider

To assess iron, serum ferritin, hemoglobin, complete blood count, and transferrin saturation are commonly used. Ferritin is the marker of body stores but can be altered by inflammation; therefore, in inflammatory contexts, values should be interpreted with caution. Transferrin saturation (TSAT) helps distinguish functional states. In complex clinical situations, the interpretation of results should be done by a healthcare professional who considers symptoms, findings, and pharmacological history [2][3].

Magnesium: biological role, clinical evidence, and limitations

Magnesium is a cofactor in hundreds of enzymatic reactions; it supports muscle function, nerve transmission, electrolyte balance, and participates in metabolic pathways related to energy. Clinical studies suggest a relationship between magnesium status and mood: a randomized trial reported improvements in depressive scores after magnesium supplementation in adults with mild-to-moderate depressive symptoms [5]. Broader systematic reviews and meta-analyses note associations between lower magnesium levels and a higher prevalence of mood disorders, but emphasize methodological variability and the need for more robust studies [6].

For muscle symptoms (cramps), the evidence synthesis is less favorable: an updated Cochrane review concludes that the evidence does not support clear clinical efficacy of magnesium supplementation for the prevention of muscle contractions in elderly or adult populations, although results are heterogeneous and some populations (e.g., pregnant women) may respond differently [7].

Forms, doses, and safety

Common oral formulations include magnesium oxide, citrate, glycinate, and chloride; bioavailability varies, and gastrointestinal tolerability profiles (e.g., diarrhea) differ. In adults with normal renal function, intakes within safety limits are generally well tolerated; in the presence of renal insufficiency, supplementation can become risky and requires medical monitoring [10].

Interactions with medications and conditions that increase the risk of deficiency

Certain medications and conditions increase the risk of iron and magnesium deficiencies. Proton pump inhibitors (PPIs) are associated with an increased risk of hypomagnesemia, likely due to altered intestinal absorption; cohort observations and pharmacovigilance studies have documented this association, especially with prolonged use [8]. Diuretics, particularly thiazides and loop diuretics, can increase urinary magnesium loss and promote hypomagnesemia, with possible repercussions on potassium and calcium [9].

For iron, some therapies and conditions that increase blood loss (e.g., heavy menstruation) or reduce absorption (some gastrointestinal diseases, prolonged use of high-buffering antacids) can lead to depletion. For this reason, clinical evaluation must include a review of drug therapy and conditions that affect absorption or losses.

Key points to remember

• Iron and magnesium are essential and involved in different processes: iron is crucial for oxygen transport and energy; magnesium supports enzymes, muscle tone, and mood components.
• Supplementation can alleviate symptoms only when a proven deficiency exists; empirical untargeted use is not recommended.
• Some medications increase the risk of deficiency (e.g., PPIs, diuretics): therapy should be evaluated with a doctor.
• The choice of form, dosage, and duration of supplementation influences outcomes and tolerability.

Limitations of evidence

It is important to distinguish between observed association in epidemiological studies and demonstration of causal effect in clinical trials. Many studies on iron and magnesium are heterogeneous in terms of deficiency definitions, studied populations, and measured outcomes; methodological quality varies, and in some areas, reviews conclude that the evidence is of low or moderate quality [2][7].

The most robust randomized trials remain limited for some clinical questions (for example, preventive therapy in people without documented deficiency). Therefore, practical recommendations must be based on individual assessment, consider possible biases, and require further studies with rigorous design to clarify benefits, optimal dosages, and target populations.

Editorial conclusion

Iron and magnesium are two nutritional protagonists with well-defined biological roles and potential practical implications for fatigue, concentration, and mood. Evidence suggests that targeted treatment of documented deficiencies can lead to clinically relevant improvements in selected subgroups. However, the variability of studies and methodological limitations require caution: the correct approach is diagnostic and personalized, based on laboratory tests and clinical evaluation. Supplementation should not replace a healthy lifestyle or the resolution of underlying medical causes. For therapeutic decisions, always consult a healthcare professional.

Editorial note

This version is an update of a previous publication drafted according to scientific accuracy and informative clarity. The article is for informational purposes and does not replace personalized clinical advice. For doubts or persistent symptoms, consult your doctor.

SCIENTIFIC RESEARCH

1. Hodgson J, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women – PREFER: randomized, placebo-controlled study. PLoS One. 2014;9(4):e94217. https://doi.org/10.1371/journal.pone.0094217
2. Miles LF, Litton E, Imberger G, Story D. Intravenous iron therapy for non‑anaemic, iron‑deficient adults. Cochrane Database Syst Rev. 2019;12:CD013084. https://doi.org/10.1002/14651858.CD013084.pub2
3. Falkingham M, Abdelhamid A, Curtis P, Fairweather‑Tait S, Dye L, Hooper L. Increasing iron and zinc in pre‑menopausal women and its effects on mood and cognition: a systematic review. Nutrients. 2014;6(11):5117–5141. https://doi.org/10.3390/nu6115117
4. Ferric carboxymaltose as treatment in women with iron‑deficiency anemia: a review. Int J Hematol. 2017. https://doi.org/10.1155/2017/9642027
5. Tarleton EK, Littenberg B. Role of magnesium supplementation in the treatment of depression: a randomized clinical trial. PLoS One. 2017;12(6):e0180067. https://doi.org/10.1371/journal.pone.0180067
6. Tarleton EK, et al. Magnesium and mood disorders: systematic review and meta‑analysis. BJPsych Open. 2018;4(4):167–179. https://doi.org/10.1192/bjo.2018.22
7. Garrison SR, et al. Magnesium for skeletal muscle cramps. Cochrane Database Syst Rev. 2020;9:CD009402. https://doi.org/10.1002/14651858.CD009402.pub3
8. Kieboom BC, et al. Proton pump inhibitors and hypomagnesemia in the general population: a population‑based cohort study. Am J Kidney Dis. 2015;66(5):775–782. https://doi.org/10.1053/j.ajkd.2015.05.012
9. Odvina CV, Mason R, Pak CY. Prevention of thiazide‑induced hypokalemia without magnesium depletion by potassium‑magnesium‑citrate. Am J Ther. 2006;13(2):101–108. https://doi.org/10.1097/01.mjt.0000149922.16098.c0
10. Castiglioni S, et al. Magnesium in prevention and therapy. Nutrients. 2015;7(10):8199–8226. https://doi.org/10.3390/nu7095388